What is it about?
Lipid nanocapsules (LNCs) have shown potential to increase the bioavailability and efficacy of orally administered drugs. However, their intestinal translocation to distal target sites and their implication in pharmacokinetic (PK)–pharmacodynamic (PD) relationships are yet to be elucidated. In this study, the effect of LNCs on the PD activity and pharmacokinetics of praziquantel (PZQ), the mainstay of schistosomiasis chemotherapy, was investigated.
Featured Image
Why is it important?
Data obtained provide evidence for the ability of oral LNCs to target distal postabsorption sites, leading to enhanced drug efficacy.
Perspectives
From a practical standpoint, PZQ–LNCs could be suggested as a potential tolerable single lower dose oral nanomedicine for more effective PZQ mass chemotherapy.
Alyaa Ramadan
faculty of Pharmacy, Alexandria University, Egypt
Read the Original
This page is a summary of: Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting, International Journal of Nanomedicine, August 2018, Dove Medical Press,
DOI: 10.2147/ijn.s167285.
You can read the full text:
Contributors
The following have contributed to this page
